Fund Name

$ Value

% Port.

COM NEW

STOCK

CALL

$ Bought

% Increased

% Reduced

$ Sold

Shares

Percent

Date

Type

% Portfolio

% Chg

$ Change

$ Held

# Shares

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the t...

Datesorted ascending	Fund Name	Type	% Portfolio	% Chg	$ Change	$ Held	# Shares
2024-05-14	OLD POINT TRUST & FINANCIAL SERVICES N A	NEW	Premium	Premium	Premium	Premium	6.00
2024-05-13	XTX Topco Ltd	SOLD OFF	Premium	Premium	Premium	Premium	-
2024-05-10	ACADIAN ASSET MANAGEMENT LLC	SOLD OFF	Premium	Premium	Premium	Premium	-
2024-05-01	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	SOLD OFF	Premium	Premium	Premium	Premium	-
2024-02-26	Virtu Financial LLC	SOLD OFF	Premium	Premium	Premium	Premium	-
2022-07-12	Minot Wealth Management LLC	UNCHANGED	Premium	Premium	Premium	Premium	615
2022-01-06	Carroll Financial Associates, Inc.	ADDED	Premium	Premium	Premium	Premium	1,000

Fund Name	# Shares	$ Value	% Port.
Carroll Financial Associates, Inc.	1,000	2,000	-
Minot Wealth Management LLC	615	151,000	0.04%
OLD POINT TRUST & FINANCIAL SERVICES N A	6.00	-	-
Virtu Financial LLC	-	-	-
CONCOURSE FINANCIAL GROUP SECURITIES, INC.	-	-	-
ACADIAN ASSET MANAGEMENT LLC	-	-	-
XTX Topco Ltd	-	-	-

Fund Name	$ Value	% Port.
Minot Wealth Management LLC	151,000	0.04%
Carroll Financial Associates, Inc.	2,000	-
Virtu Financial LLC	-	-
CONCOURSE FINANCIAL GROUP SECURITIES, INC.	-	-
ACADIAN ASSET MANAGEMENT LLC	-	-
XTX Topco Ltd	-	-
OLD POINT TRUST & FINANCIAL SERVICES N A	-	-

Fund Name	$ Sold
XTX Topco Ltd	-440
ACADIAN ASSET MANAGEMENT LLC	-
CONCOURSE FINANCIAL GROUP SECURITIES, INC.	-
Virtu Financial LLC	-14,000

CFRX - ContraFect Corp Stock Price, Fair Value and News

Which funds bought or sold CFRX recently?

Which funds are the top buyers of CFRX?

Which funds have put a big percent of portfolio in CFRX?

Trend of No. of funds that hold CFRX

Changes in Positions

Investor Breakout

Investor Churn (# Increased Holdings)

New Buys

Additions

Sold off